chronic wound care products ישראל - עברית - Ministry of Health

chronic wound care products

אדוונסמד בע"מ - כלל האוכלוסיה - מוצרים לטיפול בפצעים כרוניים

גאמונקס  - סי ישראל - עברית - Ministry of Health

גאמונקס - סי

padagis israel agencies ltd, israel - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 0.1 g/ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - gamunex is indicated as replacement therapy of primary immunodeficiency (pi) states in which severe impaiment of antibody forming capacity has been shown, such as congential agammaglobulinemia, common variable immunodeficiency, x-limked immunodeficiency with hyper igm, wiskott- aldrich syndrom, and severed combined immunodeficiencies. gamunex is also indicated in idiopathic thrombocytopenia purpura (itp) to raise platelet counts to prevent bleeding or to allow a patient with itp to undergo surgery.treatment of chronic inflammatory demyelinating polyneuropathy (cidp).

wound care & chronic care ישראל - עברית - Ministry of Health

wound care & chronic care

philtel/pharm. ltd. - מומחה - לטיפול בכל סוגי הפצעים כרוניים ואקוטיים. ציוד לבעלי סטומה

איסדרם וטרינרי ישראל - עברית - Ministry of Health

איסדרם וטרינרי

vetmarket ltd, israel - betamethasone as valerate; fusidic acid as hemihydrate - ג'ל - betamethasone as valerate 0.1 %; fusidic acid as hemihydrate 0.5 %

דספרל 0.5 גרם ישראל - עברית - Ministry of Health

דספרל 0.5 גרם

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

דואקליר ג'נואייר 34012 מקג ישראל - עברית - Ministry of Health

דואקליר ג'נואייר 34012 מקג

astrazeneca (israel) ltd - aclidinium as bromide; formoterol fumarate dihydrate - אבקה לשאיפה - formoterol fumarate dihydrate 11.8 mcg; aclidinium as bromide 340 mcg - aclidinium bromide

אבילק סירופ ישראל - עברית - Ministry of Health

אבילק סירופ

padagis israel pharmaceuticals ltd, israel - lactulose - סירופ - lactulose 66.7 g / 100 ml - lactulose - lactulose - constipation. acute and chronic hepatic encephalopathy.

בינוקריט 1000 יחבל 0.5 מל ישראל - עברית - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 2000 יחבל 1 מל ישראל - עברית - Ministry of Health

בינוקריט 2000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 30000 יחבל 0.75 מל ישראל - עברית - Ministry of Health

בינוקריט 30000 יחבל 0.75 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob